Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 18Stomach Neoplasms 16Lung Neoplasms 9Neoplasm Metastasis 5Neoplasms 4Adenocarcinoma 4Colonic Neoplasms 3Carcinoma, Hepatocellular 3Thymoma 2Rectal Neoplasms 2Non-small Cell Lung Cancer Metastatic 2Malignant Solid Tumor 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Breast Neoplasms 2Urethral Neoplasms 1Ureteral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Metastatic Small Intestinal Adenocarcinoma 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Liver Neoplasms 1Liver Diseases 1Head and Neck Neoplasms 1

Interventions

trifluridine tipiracil drug combination 1berzosertib 1Trifluridine 1Taxes 1Ramucirumab 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Irinotecan 1Endoscopy 1Endoscopic Mucosal Resection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Clinical Stage III Gastric Cancer AJCC v8 × Ramucirumab × Clear all
NCT04660760 2024-04-01

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Academic and Community Cancer Research United

Phase 2 Unknown
116 enrolled
Gastrointestinal

Clinical Stage III Gastric Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡